Denmark

Isanans is a recently established biotech company focusing on inflammatory eye disorders. The lead asset is a small molecule KCa3.1 blocker and has in animal models demonstrated significant anti-inflammatory effect and to be well-tolerated. The molecule is being developed as a topical/local treatment and the intention is to demonstrate cPoP in the most cost-efficient way, and then broaden up to a number of relevant indications after human effect has been demonstrated.

Presenter: Kamilla Rolsted, Co-founder and CEO, Isanans Pharma